Haisco Pharmaceutical Group (002653.SZ): HSK50042 tablet obtains clinical trial approval for new indications.
Huasikang (002653.SZ) announced that its subsidiary, Shanghai Huasishengnuo Pharmaceutical Technology Co., Ltd., recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The drug name is HSK50042, and the indication for this application is respiratory system diseases. HSK50042 is an orally administered, potent, highly selective small molecule inhibitor developed independently by the company. This approval marks another new indication approved for clinical trials in the field of respiratory system diseases.
Haisco Pharmaceutical Group (002653.SZ) announced that its subsidiary, Shanghai Haisishengnuo Pharmaceutical Technology Co., Ltd., recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The drug is named HSK50042, and the indication for this application is respiratory system diseases. HSK50042 is an orally administered, potent, highly selective small molecule inhibitor drug developed independently by the company. This marks another new approved clinical indication in the field of respiratory system diseases.
Related Articles
ANDRE JUICE (02218): Li Yufeng has been appointed to replace Yu Haifeng as the signing registered accountant.
SIIC Environment (00807) will distribute a final dividend of 0.011 Singapore dollars per share on May 29th.
Shenwan Hongyuan Group (06806): "22 Shen Hong 02" will pay interest on March 9th.
ANDRE JUICE (02218): Li Yufeng has been appointed to replace Yu Haifeng as the signing registered accountant.
SIIC Environment (00807) will distribute a final dividend of 0.011 Singapore dollars per share on May 29th.
Shenwan Hongyuan Group (06806): "22 Shen Hong 02" will pay interest on March 9th.
RECOMMEND
